Evidence for a Synergistic Effect of Calcium Channel Blockers with Lipid-Lowering Therapy in Retarding Progression of Coronary Atherosclerosis in Symptomatic Patients with Normal to Moderately Raised Cholesterol Levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 425-430

  Jukema, J Wouter ^a   Zwinderman, Aeilko H ^b   Van Boven, Ad J ^c   Reiber, Johan H C ^a   Van der Laarse, Arnoud ^a   Lie, Kong I ^c   Bruschke, Albert V G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atherosclerosis; Calcium channel blockers; Clinical trials; Lipids; Pravastatin

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NIFEDIPINE; PLACEBO; PRAVASTATIN; VERAPAMIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DRUG POTENTIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANTICHOLESTEREMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; PRAVASTATIN;

EID: 0029965179     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.425     Document Type: Article

References (24)

1. Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Zubiga WR, Hunter DW, Pearce MB, Bissett JK, Edmiston WA, Sawin HS, Weber FJ, Varco RL, Campbell GS, Yellin AE, Smink RD, Long JM, Hansen BJ, Chalmers TC, Meier P, Stamler J, for the Program on the Surgical Control of the Hyperlipidemias (POSCH) group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
2. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
3. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
4. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
5. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Buccuzzi SJ, Lespérance J, the CCAIT study group. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
6. MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
7. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, on behalf of the REGRESS study group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the 'Regression Growth Evaluation Statin Study' (REGRESS). Circulation. 1995;91:2528-2540.
8. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest. 1981;68:1366-1369.
9. Strickberger SA, Russek LN, Phair RD. Evidence for increased aortic plasma membrane calcium transport caused by experimental atherosclerosis in rabbits. Circ Res. 1988;62:75-80.
10. Kramsch DM, Aspen AJ, Rozler LJ. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science. 1981;213:1511-1512.
11. Loaldi A, Polese A, Montorsi P, De Cesare N, Fabbiocchi F, Ravagnani P, Guazzi MD. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol. 1989;64:433-439.
12. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, on behalf of the INTACT group investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet. 1990;335:1109-1113.
13. Waters D, Lespérance J, Francetich M, Causey D, Théroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ. A controlled clinical trial to assess the effect of calcium channel blocker on the progression of coronary atherosclerosis. Circulation, 1990;82:1940-1953.
14. Waters D, Lespérance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am Heart J. 1994;128:1309-1316.
15. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Lemaitre R, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. Circulation, 1995;91:925. Abstract.
16. Lenfant C. The calcium channel blocker scare: lessons for the future. Circulation. 1995;91:2855-2856.
17. HINT research group. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients with nifedipine or metoprolol or both. Br Heart J. 1986;56:400-413.
18. Israeli Sprint study group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-364.
19. Multicenter Diltiazem Postinfarction Trial research group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
20. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorgiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE, Young PM, Schechtman K, Perryman MB, Roberts R, and the diltiazem reinfarction group. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. N Engl J Med. 1986;315:423-429.
21. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
22. Etingin OR, Hajjar DP. Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total accumulation in human aortic tissue. Circ Res. 1990;66:185-190.
23. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-795.
24. Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res. 1990;66:1449-1452.